Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000733196 | SCV000861228 | uncertain significance | not provided | 2018-05-18 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001227516 | SCV001399877 | likely benign | Duchenne muscular dystrophy | 2024-10-18 | criteria provided, single submitter | clinical testing | |
New York Genome Center | RCV001592937 | SCV001815737 | uncertain significance | Dilated cardiomyopathy 3B | 2020-07-17 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003303219 | SCV004001546 | uncertain significance | Cardiovascular phenotype | 2023-03-31 | criteria provided, single submitter | clinical testing | The p.R2809H variant (also known as c.8426G>A), located in coding exon 57 of the DMD gene, results from a G to A substitution at nucleotide position 8426. The arginine at codon 2809 is replaced by histidine, an amino acid with highly similar properties. Based on data from gnomAD, the A allele has an overall frequency of <0.01% (4/200772) total alleles studied, with 2 hemizygote(s) observed. The highest observed frequency was <0.01% (1/18785) of African alleles. This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Natera, |
RCV001830633 | SCV002087674 | uncertain significance | Becker muscular dystrophy; Duchenne muscular dystrophy; Cardiomyopathy; Dystrophin deficiency | 2018-10-18 | no assertion criteria provided | clinical testing |